Combination of Changes in CEA and CA199 Concentration After Neoadjuvant Chemoradiotherapy Could Predict the Prognosis of Stage II/III Rectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy Followed by Total Mesorectal Excision

References

• Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018;16(7):874–901. doi:10.6004/jnccn.2018.0061
   PubMed Web of Science ®Google Scholar
• Karagkounis G, Thai L, Mace AG, et al. Prognostic implications of pathological response to neoadjuvant chemoradiation in pathologic stage III rectal cancer. Ann Surg. 2019;269(6):1117–1123. doi:10.1097/SLA.0000000000002719
   PubMed Web of Science ®Google Scholar
• Peng JY, Li ZN, Wang Y. Risk factors for local recurrence following neoadjuvant chemoradiotherapy for rectal cancers. World J Gastroenterol. 2013;19(32):5227–5237. doi:10.3748/wjg.v19.i32.5227
   PubMed Web of Science ®Google Scholar
• Jiang D, Wang X, Wang Y, et al. Mutation in BRAF and SMAD4 associated with resistance to neoadjuvant chemoradiation therapy in locally advanced rectal cancer. Virchows Arch. 2019;475(1):39–47. doi:10.1007/s00428-019-02576-y
   PubMed Web of Science ®Google Scholar
• Meng X, Wang R, Huang Z, et al. Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: association with response to neoadjuvant therapy and prognosis. Cancer Sci. 2014;105(7):818–824. doi:10.1111/cas.12421
   PubMed Web of Science ®Google Scholar
• Sun Y, Wu X, Zhang Y, et al. Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: incidence, metastatic pattern, and risk factors. Eur J Surg Oncol. 2019;45(7):1225–1231. doi:10.1016/j.ejso.2019.03.005
   PubMed Web of Science ®Google Scholar
• Yi X, Pei Q, Zhang Y, et al. MRI-based radiomics predicts tumor response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Front Oncol. 2019;9:552. doi:10.3389/fonc.2019.00552
   PubMed Web of Science ®Google Scholar
• Zhu K, Zhao Q, Yue J, et al. GOLPH3 overexpression correlates with poor response to neoadjuvant therapy and prognosis in locally advanced rectal cancer. Oncotarget. 2016;7(42):68328–68338. doi:10.18632/oncotarget.12008
   PubMedGoogle Scholar
• Monsellato I, Garibaldi E, Cassinotti E, et al. Expression levels of circulating miRNAs as biomarkers during multimodal treatment of rectal cancer – TiMiSNAR-miRNA: a substudy of the TiMiSNAR Trial (NCT03962088). Trials. 2020;21(1):678. doi:10.1186/s13063-020-04568-9
   PubMed Web of Science ®Google Scholar
• Miyakita H, Sadahiro S, Suzuki T, et al. Tumor-infiltrating lymphocytes in biopsy specimens obtained 7 days after starting chemoradiotherapy for rectal cancer are predictors of the response to chemoradiotherapy. Oncology. 2020;98(12):869–875. doi:10.1159/000508922
   PubMed Web of Science ®Google Scholar
• Suzuki T, Sadahiro S, Tanaka A, et al. Predictive markers of chemoradiotherapy for rectal cancer: comparison of biopsy specimens taken before and about 1 week after the start of chemoradiotherapy. Int J Clin Oncol. 2015;20(6):1130–1139. doi:10.1007/s10147-015-0822-7
   PubMed Web of Science ®Google Scholar
• Han L, Mo S, Xiang W, et al. Comparison of four lymph node staging systems for predicting prognosis for stage IV rectum cancer. Ann Transl Med. 2020;8(4):111. doi:10.21037/atm.2019.12.90
   PubMed Web of Science ®Google Scholar
• Chung MJ, Lee JH, Lee JH, et al. Adjuvant chemotherapy in rectal cancer patients treated with preoperative chemoradiation and total mesorectal excision: a multicenter and retrospective propensity-score matching study. Int J Radiat Oncol Biol Phys. 2019;103(2):438–448. doi:10.1016/j.ijrobp.2018.09.016
   PubMed Web of Science ®Google Scholar
• Lai S, Huang L, Luo S, et al. Systemic inflammatory indices predict tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Oncol Lett. 2020;20(3):2763–2770. doi:10.3892/ol.2020.11812
   PubMed Web of Science ®Google Scholar
• Lee IH, Hwang S, Lee SJ, et al. Systemic inflammatory response after preoperative chemoradiotherapy can affect oncologic outcomes in locally advanced rectal cancer. Anticancer Res. 2017;37(3):1459–1465.
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Wyrwicz L, Tiret E, et al. Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv22–iv40. doi:10.1093/annonc/mdx224
   PubMed Web of Science ®Google Scholar
• Watanabe T, Muro K, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23(1):1–34. doi:10.1007/s10147-017-1101-6
   PubMed Web of Science ®Google Scholar
• Burke HB. Overall survival vs disease-specific survival. JAMA Oncol. 2018;4(4):586. doi:10.1001/jamaoncol.2016.6786
   PubMed Web of Science ®Google Scholar
• Mehta RS, Barlow WE, Albain KS, et al. Overall survival with fulvestrant plus anastrozole in metastatic breast cancer. N Engl J Med. 2019;380(13):1226–1234. doi:10.1056/NEJMoa1811714
   PubMed Web of Science ®Google Scholar
• Saad ED, Squifflet P, Burzykowski T, et al. Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. Lancet Oncol. 2019;20(3):361–370. doi:10.1016/S1470-2045(18)30750-2
   PubMed Web of Science ®Google Scholar
• Carter JV, Pan J, Rai SN, Galandiuk S. ROC-ing along: evaluation and interpretation of receiver operating characteristic curves. Surgery. 2016;159(6):1638–1645. doi:10.1016/j.surg.2015.12.029
   PubMed Web of Science ®Google Scholar
• Luo H, Xu Y, Zhang X. Kaplan-Meier curve of retrospective study: do not misuse it! Int J Cardiol. 2017;247:28. doi:10.1016/j.ijcard.2017.04.043
   PubMed Web of Science ®Google Scholar
• Yang S. Interim monitoring using the adaptively weighted log-rank test in clinical trials for survival outcomes. Stat Med. 2019;38(4):601–612. doi:10.1002/sim.7958
   PubMed Web of Science ®Google Scholar
• Allgulander C, Fisher LD. Survival analysis (or time to an event analysis), and the Cox regression model–methods for longitudinal psychiatric research. Acta Psychiatr Scand. 1986;74(6):529–535. doi:10.1111/j.1600-0447.1986.tb06279.x
   PubMed Web of Science ®Google Scholar
• Austin PC. Statistical power to detect violation of the proportional hazards assumption when using the Cox regression model. J Stat Comput Simul. 2018;88(3):533–552. doi:10.1080/00949655.2017.1397151
   PubMed Web of Science ®Google Scholar
• Chen MH, Ibrahim JG, Shao QM. Maximum likelihood inference for the cox regression model with applications to missing covariates. J Multivar Anal. 2009;100(9):2018–2030. doi:10.1016/j.jmva.2009.03.013
   PubMed Web of Science ®Google Scholar
• Pazdirek F, Minarik M, Benesova L, et al. Monitoring of early changes of circulating tumor DNA in the plasma of rectal cancer patients receiving neoadjuvant concomitant chemoradiotherapy: evaluation for prognosis and prediction of therapeutic response. Front Oncol. 2020;10:1028. doi:10.3389/fonc.2020.01028
   PubMed Web of Science ®Google Scholar
• Tan Y, Fu D, Li D, et al. Predictors and risk factors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer: a population-based analysis. Front Oncol. 2019;9:497. doi:10.3389/fonc.2019.00497
   PubMed Web of Science ®Google Scholar
• Prampolini F, Taschini S, Pecchi A, et al. Magnetic resonance imaging performed before and after preoperative chemoradiotherapy in rectal cancer: predictive factors of recurrence and prognostic significance of MR-detected extramural venous invasion. Abdom Radiol. 2020;45(10):2941–2949. doi:10.1007/s00261-018-1838-z
   PubMed Web of Science ®Google Scholar
• Shao L, Liu Z, Feng L, et al. Multiparametric MRI and whole slide image-based pretreatment prediction of pathological response to neoadjuvant chemoradiotherapy in rectal cancer: a multicenter radiopathomic study. Ann Surg Oncol. 2020;27(11):4296–4306. doi:10.1245/s10434-020-08659-4
   PubMed Web of Science ®Google Scholar
• Alvarez-Jimenez C, Antunes JT, Talasila N, et al. Radiomic texture and shape descriptors of the rectal environment on post-chemoradiation T2-weighted MRI are associated with pathologic tumor stage regression in rectal cancers: a retrospective, multi-institution study. Cancers. 2020;12(8):2027. doi:10.3390/cancers12082027
   PubMed Web of Science ®Google Scholar
• Zhang H, Huang Y, Sun G, et al. Rectal cancer patients with downstaging after neoadjuvant chemoradiotherapy and radical resection do not benefit from adjuvant chemotherapy. Ann Transl Med. 2020;8(12):743. doi:10.21037/atm-20-1278
   PubMed Web of Science ®Google Scholar
• Voboril R, Rychterova V, Voborilova J, Kubecova M, Fanta J, Dvorak J. NF-κB/p65 expression before and after treatment in rectal cancer patients undergoing neoadjuvant (chemo)radiotherapy and surgery: prognostic marker for disease progression and survival. Neoplasma. 2016;63(3):462–470. doi:10.4149/317_151013N525
   PubMed Web of Science ®Google Scholar
• Qin CJ, Song XM, Chen ZH, et al. XRCC2 as a predictive biomarker for radioresistance in locally advanced rectal cancer patients undergoing preoperative radiotherapy. Oncotarget. 2015;6(31):32193–32204. doi:10.18632/oncotarget.4975
   PubMedGoogle Scholar
• Zaanan A, Park JM, Tougeron D, et al. Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinoma. Int J Cancer. 2015;137(6):1498–1502. doi:10.1002/ijc.29496
   PubMed Web of Science ®Google Scholar
• Keller DS, Berho M, Perez RO, Wexner SD, Chand M. The multidisciplinary management of rectal cancer. Nat Rev Gastroenterol Hepatol. 2020;17(7):414–429. doi:10.1038/s41575-020-0275-y
   PubMed Web of Science ®Google Scholar
• Berho M, Bejarano PA. Rectal cancer and the pathologist. Minerva Chir. 2018;73(6):534–547. doi:10.23736/S0026-4733.18.07739-8
   PubMed Web of Science ®Google Scholar
• Kennedy ED, Simunovic M, Jhaveri K, et al. Safety and feasibility of using magnetic resonance imaging criteria to identify patients with “good prognosis” rectal cancer eligible for primary surgery: the phase 2 nonrandomized quicksilver clinical trial. JAMA Oncol. 2019;5(7):961–966. doi:10.1001/jamaoncol.2019.0186
   PubMed Web of Science ®Google Scholar
• Lim TS, Rhee H, Kim GM, et al. Alpha-fetoprotein, des-gamma-carboxy prothrombin, and modified RECIST response as predictors of survival after transarterial radioembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2019;30(8):1194–200.e1. doi:10.1016/j.jvir.2019.03.016
   PubMed Web of Science ®Google Scholar
• Motoi F, Rikiyama T, Katayose Y, Egawa S, Unno M. Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based on RECIST guidelines. Ann Surg Oncol. 2011;18(2):371–379. doi:10.1245/s10434-010-1311-x
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Bonfrer JM, Kulpa J, et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer. 2005;15(5):679–691. doi:10.1111/j.1525-1438.2005.00130.x
   PubMed Web of Science ®Google Scholar
• Mo CJ, Hu ZJ, Qin SZ, et al. Diagnostic value of platelet-lymphocyte ratio and hemoglobin-platelet ratio in patients with rectal cancer. J Clin Lab Anal. 2020;34(4):e23153. doi:10.1002/jcla.23153
   PubMed Web of Science ®Google Scholar
• Neki K, Eto K, Kosuge M, et al. Identification of the risk factors for recurrence of stage III colorectal cancer. Anticancer Res. 2019;39(10):5721–5724. doi:10.21873/anticanres.13772
   PubMed Web of Science ®Google Scholar
• Baqar AR, Wilkins S, Staples M, Angus Lee CH, Oliva K, McMurrick P. The role of preoperative CEA in the management of colorectal cancer: a cohort study from two cancer centres. Int J Surg. 2019;64:10–15. doi:10.1016/j.ijsu.2019.02.014
   PubMed Web of Science ®Google Scholar
• Camacho-Leal P, Stanners CP. The human carcinoembryonic antigen (CEA) GPI anchor mediates anoikis inhibition by inactivation of the intrinsic death pathway. Oncogene. 2008;27(11):1545–1553. doi:10.1038/sj.onc.1210789
   PubMed Web of Science ®Google Scholar
• Nicholson TB, Stanners CP. Specific inhibition of GPI-anchored protein function by homing and self-association of specific GPI anchors. J Cell Biol. 2006;175(4):647–659. doi:10.1083/jcb.200605001
   PubMed Web of Science ®Google Scholar
• Cheong C, Shin JS, Suh KW. Prognostic value of changes in serum carcinoembryonic antigen levels for preoperative chemoradiotherapy response in locally advanced rectal cancer. World J Gastroenterol. 2020;26(44):7022–7035. doi:10.3748/wjg.v26.i44.7022
   PubMed Web of Science ®Google Scholar
• Yang KL, Yang SH, Liang WY, et al. Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery. Radiat Oncol. 2013;8:43. doi:10.1186/1748-717X-8-43
   PubMed Web of Science ®Google Scholar
• Gold DV, Modrak DE, Ying Z, Cardillo TM, Sharkey RM, Goldenberg DM. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J Clin Oncol. 2006;24(2):252–258. doi:10.1200/JCO.2005.02.8282
   PubMed Web of Science ®Google Scholar
• Remmers N, Anderson JM, Linde EM, et al. Aberrant expression of mucin core proteins and o-linked glycans associated with progression of pancreatic cancer. Clin Cancer Res. 2013;19(8):1981–1993. doi:10.1158/1078-0432.CCR-12-2662
   PubMed Web of Science ®Google Scholar
• Zheng Z, Wang X, Huang Y, Lu X, Chi P. Predictive value of changes in the level of carbohydrate antigen 19-9 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Colorectal Dis. 2020;22(12):2068–2077. doi:10.1111/codi.15355
   PubMed Web of Science ®Google Scholar
• Kato S, Honda K. CA19-9 as a therapeutic target in pancreatitis. Ann Transl Med. 2019;7(Suppl 8):S318. doi:10.21037/atm.2019.09.161
   PubMed Web of Science ®Google Scholar